GenPath has recently introduced Inherited Cancer testing. We now offer our patients and their families important tests linked to hereditary cancer such as BRCA1/2 and Lynch syndrome. Inherited cancer testing adds to our growing portfolio of testing that is unmatched among cancer focused diagnostic laboratories. Our turnaround time and result reports are among the best in the industry. If you would like more information please contact us.
In The News
Our parent company, BioReference Laboratories, announced record revenues for the third quarter of 2014. The company recorded Q3FY14 revenues of $222,053 million, representing an increase of 20% over the $185,427 million recorded in Q3FY13. We are proud of our continued success and will never cease to innovate towards better patient care.